The long-time biases held by investors in potentially high-value diagnostics persist: that companies don’t have all that much pricing power; and those that succeed in technology development often balk – certainly early on – at investing in the kinds of studies that would prove the technology should be practice-changing. Little happened to alter that view during the year.
If anything, the biggest newsmaker in 2014 heightened concerns over the business model. The US Food and Drug Administration finally...
